About Us 

StableBody Technologies, LLC is a privately held protein engineering company based in Madison, WI.  SBT is founded and managed by individuals having almost 100 years of combined scientific, business, and finance experience working in early stage technology firms and large Fortune 50 size corporations.


SBT is committed to become an industry leader for the stabilization and affinity optimization of proteins , for applications in clinically relevant biomarker detection and treatment, environmental and bio-threat detection and countermeasures. Such proteins include antibodies  generally found in the blood that detect and destroy invaders, like bacteria and viruses.


SBT’s platform combines a proprietary bioinformatics system with proprietary protein expression and production systems to produce “robust” recombinant proteins and antibody fragments such as single chain antibody fragments (scFvs) . These “robust” proteins are capable of withstanding elevated temperatures in harsh environments while maintaining high specificity and sensitivity to target.


SBT is focused on the development of stable and affinity optimized clinically relevant scFvs. SBT addresses the generation of engineered proteins through the use of a proprietary algorithm for generating specific, high affinity and stable scFvs to clinically relevant biomarkers. SBT’s business model is centered on development of an internal pipeline of antibody and protein-based, therapeutic and diagnostic candidates such as the newly developed SBT anti-CD45 scFv.  Strategic development agreements with major pharmaceutical companies provide milestone revenue and long-term royalty streams.  For our in house pipeline development, SBT mitigates the risk and uncertainty associated with target discovery and validation.  Furthermore, SBT expects to partner successful candidates to fully exploit its core competencies in the design and affinity optimization of new IP protected scFvs.


SBT continually increases the functionality of its proprietary bioinformatics system, providing increased  accuracy of select amino acid substitutions for use in product construct design and development.   These tools reduce development expenses by decreasing the design, expression, and production time.


Objective of Core Platform Technology

  • improve protein thermodynamic stability to extend product shelf life and reduce costs,
  • allow protein/kit storage and use in a wider range of temperature conditions
  • eliminate cold chain (refrigeration/freezing) issues for shipping and storage
  • improve protein binding properties for higher sensitivity and specificity in detection kits
  • Reduce reagent usage due to improved protein properties thereby reducing the costs of goods sold
  • improve manufacturing efficiencies for shorter production times, higher yields and lowering costs
  • reduce research, development and manufacturing costs to bring products to market faster



    StableBody Technologies, LLC

    4675 Signature Drive

    Middleton, WI  53562


    H. Rossiter Horn, RPh

    Chief Executive Officer